BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $912,402 | -71.3% | 34,600 | -81.3% | 0.01% | -66.7% |
| Q2 2023 | $3,183,084 | -12.2% | 185,063 | -15.4% | 0.02% | -4.5% |
| Q1 2023 | $3,625,151 | +6769.8% | 218,646 | +3057.3% | 0.02% | – |
| Q4 2022 | $52,769 | -98.8% | 6,925 | -98.5% | 0.00% | -100.0% |
| Q3 2022 | $4,562,000 | +108.5% | 458,936 | +90.4% | 0.03% | +100.0% |
| Q2 2022 | $2,188,000 | -12.6% | 240,996 | -2.3% | 0.01% | -38.1% |
| Q1 2022 | $2,504,000 | +137.1% | 246,731 | +289.8% | 0.02% | +110.0% |
| Q4 2021 | $1,056,000 | +93.8% | 63,292 | +443.9% | 0.01% | +42.9% |
| Q3 2021 | $545,000 | +137.0% | 11,636 | +211.3% | 0.01% | +133.3% |
| Q1 2021 | $230,000 | -59.2% | 3,738 | -52.8% | 0.00% | -62.5% |
| Q4 2020 | $564,000 | -47.8% | 7,926 | -72.5% | 0.01% | -50.0% |
| Q3 2020 | $1,081,000 | – | 28,801 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $82,353,000 | 42.93% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $792,257,000 | 4.46% |
| Perceptive Advisors | 6,706,268 | $143,983,000 | 3.88% |
| Cormorant Asset Management, LP | 2,617,566 | $56,199,000 | 3.42% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $571,553,000 | 2.98% |
| SC US (TTGP), LTD. | 2,544,738 | $54,636,000 | 2.42% |
| HHLR ADVISORS, LTD. | 4,388,690 | $94,225,000 | 1.30% |
| Fernwood Investment Management, LLC | 95,200 | $2,044,000 | 1.01% |
| AMERICAN INTERNATIONAL GROUP, INC. | 6,746,511 | $144,847,000 | 0.58% |
| Ratan Capital Management LP | 46,548 | $999,000 | 0.53% |